BNTX Stock Analysis: BioNTech SE | NASDAQ

mRNA Vaccines, Immunotherapies, Oncology Drugs, Infectious Disease

Total Rating 27

Safety 90

Buy Signal -0.32

Biotechnology
Sub-Industry Rotation: +3.7

Market Cap: 22.5B
Avg Turnover: 90.4M

Risk 3d forecast

Volatility41.1%

VaR 5^th Pctl6.07%

VaR vs Median-8.66%

Reward TTM

Sharpe Ratio-0.31

Rel. Str. IBD16.9

Rel. Str. Peer Group25.8 pctl

Character TTM

Beta0.778

Beta Downside1.133

Hurst Exponent0.570

Choppyness35.7%

Drawdowns 3y

Max DD33.88%

CAGR/Max DD-0.13

CAGR/Mean DD-0.26

EPS (Earnings per Share)

Last SUE: 1.18
Qual. Beats: 1

Revenue

Rev. CAGR: -6.63%
Rev. Trend: -54.6%

Last SUE: 0.97
Qual. Beats: 1

Warnings

High Debt/EBITDA With Thin Interest Coverage

High Debt While Negative Cash Flow

Interest Coverage Ratio Critical

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 7.1 years of data, until 10/2026

Jan +1.2% 0

Feb -5.2% 60

Mar +0.2% 0

Apr -2.1% 0

May -1.8% 0

Jun +4.3% 11

Jul +4.1% 60

Aug -0.9% 11

Sep -0.3% 11

Oct +0.9% 0

Nov +7.5% 60

Dec -5.6% 11

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: BNTX BioNTech SE

BioNTech SE is a German biotechnology company headquartered in Mainz that develops and commercializes immunotherapies, with its core technology built around messenger RNA (mRNA) platforms. Originally incorporated in 2008, the company gained global recognition through its BNT162 mRNA vaccine developed for SARS-CoV-2, which serves as a foundation for its broader infectious disease and oncology programs.

The company maintains a deep clinical pipeline that extends well beyond COVID-19, with a strong emphasis on oncology candidates across multiple phases of development, including Phase III assets such as Gotistobart (non-small cell lung cancer), Pumitamig (small cell lung cancer and triple-negative breast cancer), and Trastuzumab pamirtecan (metastatic breast cancer). Earlier-stage oncology work targets solid tumors, colorectal cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, mesothelioma, neuroendocrine neoplasms, and pancreatic ductal adenocarcinoma.

In parallel, BioNTech is advancing infectious disease vaccines against pathogens including mpox, tuberculosis, malaria, influenza, and SARS-CoV-2, illustrating how its mRNA platform is applied across therapeutic areas. Listed on NASDAQ under the ticker BNTX since its 2019 IPO, the company operates within the large-cap biotechnology segment, where platform-based developers typically face long regulatory timelines and significant R&D investment before products reach commercialization.

Headlines to Watch Out For

COVID vaccine revenue declines sharply as demand normalizes
Oncology Phase III readouts for Pumitamig and Gotistobart approach
Strong cash reserves fund oncology pipeline expansion and M&A activity

Piotroski VR-10 (Strict) 0.0

Net Income: -1.48b TTM > 0 and > 6% of Revenue
FCF/TA: -0.02 > 0.02 and ΔFCF/TA 0.38 > 1.0
NWC/Revenue: 573.4% < 20% (prev 431.7%; Δ 141.8% < -1%)
CFO/TA -0.01 > 3% & CFO -247.6m > Net Income -1.48b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.55 > 1.5 & < 3
Outstanding Shares: last quarter (253.0m) vs 12m ago 5.78% < -2%
Gross Margin: 69.91% > 18% (prev 82.49%; Δ -12.58% > 0.5%)
Asset Turnover: 11.63% > 50% (prev 14.77%; Δ -3.14% > 0%)
Interest Coverage Ratio: -52.90 > 6 (EBIT TTM -1.41b / Interest Expense TTM 26.7m)

Altman Z'' 10.00

A: 0.69 (Total Current Assets 15.7b - Total Current Liabilities 1.83b) / Total Assets 20.2b
B: 0.83 (Retained Earnings 16.8b / Total Assets 20.2b)
C: -0.07 (EBIT TTM -1.41b / Avg Total Assets 20.8b)
D: 7.19 (Book Value of Equity 17.7b / Total Liabilities 2.46b)
Altman-Z'' = 14.31 = AAA

Beneish M -2.94

DSRI: 1.24 (Receivables 666.3m/699.7m, Revenue 2.41b/3.15b)
GMI: 1.18 (GM 82.49% / 69.91%)
AQI: 0.83 (AQ_t 0.17 / AQ_t-1 0.20)
SGI: 0.77 (Revenue 2.41b / 3.15b)
TATA: -0.06 (NI -1.48b - CFO -247.6m) / TA 20.2b)
Beneish M = -2.94 (Cap -4..+1) = A

What is the price of BNTX shares?

As of November 12, 2026, the stock is trading at USD 87.65 with a total of 764,875 shares traded. Over the past week, the price has changed by -3.36%, over one month by -8.55%, over three months by -5.55% and over the past year by -19.33%.

Current recommended Stop Loss: 84.20 (which is 3.9% or 1.2 ATR below the current price).

Is BNTX a buy, sell or hold?

BioNTech SE has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy BNTX.

StrongBuy: 13
Buy: 1
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the BNTX price?

Analysts Target Price	116.9	33.4%

BioNTech SE (BNTX) - Fundamental Data Overview as of 06 November 2026

Market Cap USD = 22.5b (22.5b USD * 1.0 USD.USD)
Market Cap EUR = 20.3b (22.5b USD * 0.90079998970032 USD.EUR)
P/E Forward = 7.0373
P/S = 8.4857
P/B = 1.1022
P/EG = 0.046
Revenue TTM = 2.41b EUR
EBIT TTM = -1.41b EUR
EBITDA TTM = -527.8m EUR
Long Term Debt = 110.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 104.4m EUR (from shortTermDebt, last quarter)
Debt = 551.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 191.6m
Net Debt = -9.65b EUR (calculated: Debt 551.4m - CCE 10.2b)
Enterprise Value = 10.6b EUR (20.3b + Debt 551.4m - CCE 10.2b)
Interest Coverage Ratio = -52.90 (Ebit TTM -1.41b / Interest Expense TTM 26.7m)
EV/FCF = -23.25x (Enterprise Value 10.6b / FCF TTM -456.2m)
FCF Yield = -4.30% (FCF TTM -456.2m / Enterprise Value 10.6b)
FCF Margin = -18.90% (FCF TTM -456.2m / Revenue TTM 2.41b)
Net Margin = -61.28% (Net Income TTM -1.48b / Revenue TTM 2.41b)
Gross Margin = 69.91% ((Revenue TTM 2.41b - Cost of Revenue TTM 726.3m) / Revenue TTM)
Gross Margin QoQ = 91.99% (prev 8.14%)
Tobins Q-Ratio = 0.53 (Enterprise Value 10.6b / Total Assets 20.2b)
Interest Expense / Debt = 4.84% (Interest Expense 26.7m / Debt 551.4m)
Taxrate = 16.89% (37.5m / 222.0m)
NOPAT = -1.17b (EBIT -1.41b * (1 - 16.89%)) [loss with tax shield]
Current Ratio = 8.55 (Total Current Assets 15.7b / Total Current Liabilities 1.83b)
Debt / Equity = 0.03 (Debt 551.4m / totalStockholderEquity, last quarter 17.7b)
Debt / EBITDA = 18.28 (negative EBITDA) (Net Debt -9.65b / EBITDA -527.8m)
Debt / FCF = 21.15 (negative FCF - burning cash) (Net Debt -9.65b / FCF TTM -456.2m)
Total Stockholder Equity = 18.3b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.13% (Net Income -1.48b / Total Assets 20.2b)
RoE = -8.06% (Net Income TTM -1.48b / Total Stockholder Equity 18.3b)
RoCE = -7.65% (EBIT -1.41b / Capital Employed (Equity 18.3b + L.T.Debt 110.8m))
RoIC = -6.41% (negative operating profit) (NOPAT -1.17b / Invested Capital 18.3b)
WACC = 8.15% (E(20.3b)/V(20.8b) * Re(8.26%) + D(551.4m)/V(20.8b) * Rd(4.84%) * (1-Tc(0.17)))
Discount Rate = 8.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.02 | Cagr: 2.81%
[DCF] Fair Price = unknown (Cash Flow -456.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.18 | # QB: 1
Revenue Correlation: -54.57 | Revenue CAGR: -6.63% | SUE: 0.97 | # QB: 1
EPS current Quarter (2027-03-31): EPS=-1.70 | Chg30d=+0.00% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=-4.75 | Chg30d=-1.98% | Revisions=+29% | GrowthEPS=-888.9% | GrowthRev=-38.1%
EPS next Year (2027-12-31): EPS=-4.86 | Chg30d=+0.98% | Revisions=-29% | GrowthEPS=-2.5% | GrowthRev=+1.3%
[Analyst] Revisions Ratio: +0% (up=4, down=4)